210 related articles for article (PubMed ID: 31221551)
1. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.
Pérez-Matute P; Íñiguez M; Villanueva-Millán MJ; Recio-Fernández E; Vázquez AM; Sánchez SC; Morano LE; Oteo JA
Eur J Intern Med; 2019 Sep; 67():47-58. PubMed ID: 31221551
[TBL] [Abstract][Full Text] [Related]
2. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
3. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.
Chuaypen N; Jinato T; Avihingsanon A; Chirapongsathorn S; Cheevadhanarak S; Nookaew I; Tanaka Y; Tangkijvanich P
J Infect Dis; 2021 Oct; 224(8):1410-1421. PubMed ID: 33598686
[TBL] [Abstract][Full Text] [Related]
4. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
5. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents.
Pinchera B; Moriello NS; Buonomo AR; Zappulo E; Viceconte G; Villari R; Gentile I
Microb Pathog; 2023 Feb; 175():105968. PubMed ID: 36626945
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection.
Chuaypen N; Jinato T; Avihingsanon A; Nookaew I; Tanaka Y; Tangkijvanich P
Sci Rep; 2023 Sep; 13(1):14413. PubMed ID: 37660163
[TBL] [Abstract][Full Text] [Related]
7. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
8. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
9. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
10. Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment.
Biliotti E; Giampaoli O; Sciubba F; Marini F; Tomassini A; Palazzo D; Capuani G; Esvan R; Spaziante M; Taliani G; Miccheli A
Biomed Pharmacother; 2021 Nov; 143():112217. PubMed ID: 34560544
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
13. Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
Putra J; Schiano TD; Fiel MI
Histopathology; 2018 May; 72(6):990-996. PubMed ID: 29235144
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
[TBL] [Abstract][Full Text] [Related]
15. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
16. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
18. [Histological evaluation of liver in chronic hepatitis C after direct-acting antiviral agents treatment].
Jiang LN; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):184-187. PubMed ID: 29804391
[TBL] [Abstract][Full Text] [Related]
19. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
20. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]